TY - JOUR
T1 - Synergistic Stimulation of Prostaglandin E2 Release by Epidermal Growth Factor and a Tumor Promoter Anthralin from Primary Cultures of Mouse Epidermal Cells
AU - Aizu, Eriko
AU - Yamamoto, Satoshi
AU - Nishikawa, Kiyotaka
AU - Kato, Ryuichi
PY - 1991/1
Y1 - 1991/1
N2 - The tumor promoter anthralin stimulated prostaglandin E2 (PGE2) and arachidonic acid release from primary cultures of mouse epidermal cells. Epidermal growth factor (EGF) hardly stimulated PGE2 release by itself; however, a combination of anthralin and EGF synergistically stimulated PGE2 release. Neither anthralin, EGF nor EGF plus anthralin affected the incorporation of arachidonic acid into cellular phospholipids at least up to 2 hr after the stimulation by these agents. In the presence of EGF, however, [3H]arachidonic aicd in the medium decreased substantially 4 -8hr after the addition of this agent, indicating that EGF suppresses [3H]arachidonic acid release and stimulates the incorporation of [3H]arachidonic acid into the cells during this time period. Cellular cyclooxygenase activity was increased by treating the cells either with anthralin or EGF, and it was synergistically increased by EGF plus anthralin. Both cycloheximide and actinomycin D inhibited the increase in cyclooxygenase activity caused by EGF plus anthralin. These results indicate that the synergistic stimulation of PGE2 release caused by EGF plus anthralin is due to a synergistic stimulation of arachidonic acid release (in the early phase of stimulation) and a synergistic increase in cyclooxygenase activity, probably a synergistic induction of cyclooxygenase, by these agents.
AB - The tumor promoter anthralin stimulated prostaglandin E2 (PGE2) and arachidonic acid release from primary cultures of mouse epidermal cells. Epidermal growth factor (EGF) hardly stimulated PGE2 release by itself; however, a combination of anthralin and EGF synergistically stimulated PGE2 release. Neither anthralin, EGF nor EGF plus anthralin affected the incorporation of arachidonic acid into cellular phospholipids at least up to 2 hr after the stimulation by these agents. In the presence of EGF, however, [3H]arachidonic aicd in the medium decreased substantially 4 -8hr after the addition of this agent, indicating that EGF suppresses [3H]arachidonic acid release and stimulates the incorporation of [3H]arachidonic acid into the cells during this time period. Cellular cyclooxygenase activity was increased by treating the cells either with anthralin or EGF, and it was synergistically increased by EGF plus anthralin. Both cycloheximide and actinomycin D inhibited the increase in cyclooxygenase activity caused by EGF plus anthralin. These results indicate that the synergistic stimulation of PGE2 release caused by EGF plus anthralin is due to a synergistic stimulation of arachidonic acid release (in the early phase of stimulation) and a synergistic increase in cyclooxygenase activity, probably a synergistic induction of cyclooxygenase, by these agents.
UR - http://www.scopus.com/inward/record.url?scp=0026354542&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026354542&partnerID=8YFLogxK
U2 - 10.1254/jjp.57.361
DO - 10.1254/jjp.57.361
M3 - Article
C2 - 1813662
AN - SCOPUS:0026354542
SN - 0021-5198
VL - 57
SP - 361
EP - 366
JO - Japanese Journal of Pharmacology
JF - Japanese Journal of Pharmacology
IS - 3
ER -